<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00005997</url>
  </required_header>
  <id_info>
    <org_study_id>CWRU2299</org_study_id>
    <secondary_id>U01CA063200</secondary_id>
    <secondary_id>P30CA043703</secondary_id>
    <secondary_id>CWRU-2299</secondary_id>
    <secondary_id>NCI-96</secondary_id>
    <nct_id>NCT00005997</nct_id>
  </id_info>
  <brief_title>Rebeccamycin Analogue in Treating Patients With Advanced Liver and/or Biliary Cancer</brief_title>
  <official_title>Phase II and Pharmacokinetic Trial of Rebeccamycin Analog in Hepatobiliary Cancers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Case Comprehensive Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Case Comprehensive Cancer Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so&#xD;
      they stop growing or die.&#xD;
&#xD;
      PURPOSE: Phase II trial to study the effectiveness of rebeccamycin analogue in treating&#xD;
      patients who have advanced liver and/or biliary cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the response rate in patients with advanced hepatobiliary carcinoma treated&#xD;
           with rebeccamycin analogue.&#xD;
&#xD;
        -  Assess the toxicity associated with this drug in this patient population.&#xD;
&#xD;
        -  Evaluate the survival of this patient population treated with this drug.&#xD;
&#xD;
        -  Determine the pharmacokinetics of this drug in this patient population.&#xD;
&#xD;
      OUTLINE: This is a partial dose-escalation study.&#xD;
&#xD;
      Patients receive rebeccamycin analogue IV over 1 hour daily on days 1-5. Treatment repeats&#xD;
      every 3 weeks in the absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      Patients are assigned to 1 of 2 cohorts according to hepatic dysfunction. (Cohort I closed to&#xD;
      accrual as of 11/1/03.)&#xD;
&#xD;
        -  Cohort I (closed to accrual as of 11/1/03): Patients receive a fixed dose of&#xD;
           rebeccamycin analogue.&#xD;
&#xD;
        -  Cohort II: Cohorts of 3-6 patients receive escalating doses of rebeccamycin analogue&#xD;
           until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose&#xD;
           preceding that at which 2 of 6 patients experience dose-limiting toxicity.&#xD;
&#xD;
      Patients are followed every 3 months.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 12-37 patients will be accrued for this study within 6-37&#xD;
      months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    slow accrual for Cohort II&#xD;
  </why_stopped>
  <start_date>April 1999</start_date>
  <completion_date type="Actual">November 2005</completion_date>
  <primary_completion_date type="Actual">April 2005</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Determine the response rate in patients with advanced hepatobiliary carcinoma treated with rebeccamycin analogue.</measure>
    <time_frame>Patients are followed every 3 months.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assess the toxicity associated with this drug in this patient population.</measure>
    <time_frame>Patients are followed every 3 months.</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">72</enrollment>
  <condition>Extrahepatic Bile Duct Cancer</condition>
  <condition>Gallbladder Cancer</condition>
  <condition>Liver Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>becatecarin</intervention_name>
    <description>Cohorts of 3-6 patients receive escalating doses of rebeccamycin analogue until the maximum tolerated dose (MTD) is determined.</description>
    <other_name>DEAE-rebeccamycin</other_name>
    <other_name>rebeccamycin analogue</other_name>
    <other_name>rebeccamycin analogue, tartrate salt</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Diagnosis of advanced hepatobiliary carcinoma not amenable to conventional surgery&#xD;
&#xD;
               -  Gall bladder carcinoma&#xD;
&#xD;
               -  Cholangiocarcinoma&#xD;
&#xD;
               -  Carcinoma of the ampulla&#xD;
&#xD;
               -  Hepatocellular carcinoma (eligible for cohort II only)&#xD;
&#xD;
          -  Measurable disease&#xD;
&#xD;
          -  No known brain metastases&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  ECOG 0-2&#xD;
&#xD;
        Life expectancy:&#xD;
&#xD;
          -  At least 12 weeks&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  WBC at least 3,000/mm^3&#xD;
&#xD;
          -  Granulocyte count at least 1,500/mm^3&#xD;
&#xD;
          -  Platelet count at least 100,000/mm^3&#xD;
&#xD;
          -  Hemoglobin greater than 10 g/dL&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  Bilirubin less than 3 mg/dL&#xD;
&#xD;
               -  Cohort I (closed to accrual as of 11/1/03)&#xD;
&#xD;
                    -  Bilirubin no greater than 1.5 mg/dL&#xD;
&#xD;
                    -  AST no greater than 2.5 times upper limit of normal (ULN)&#xD;
&#xD;
               -  Cohort II&#xD;
&#xD;
                    -  Bilirubin greater than 1.5 mg/dL and less than 3 mg/dL OR&#xD;
&#xD;
                    -  Bilirubin no greater 1.5 mg/dL AND AST greater than 2.5 times ULN&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  Creatinine normal OR&#xD;
&#xD;
          -  Creatinine clearance at least 60 mL/min&#xD;
&#xD;
        Cardiovascular:&#xD;
&#xD;
          -  No New York Heart Association class III or IV heart disease&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Chemotherapy:&#xD;
&#xD;
          -  No prior chemotherapy for cholangiocarcinoma or hepatobiliary carcinoma&#xD;
&#xD;
        Endocrine therapy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Radiotherapy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Surgery:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  No concurrent combination antiviral therapy for HIV-positive patients&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Afshin Dowlati, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Ireland Cancer Center at University Hospitals Case Medical Center, Case Comprehensive Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Comprehensive Cancer Center at University of Alabama at Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294-3300</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ireland Cancer Center at University Hospitals Case Medical Center, Case Comprehensive Cancer Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106-5065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hillman Cancer Center at University of Pittsburgh Cancer Institute</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Dowlati A, Posey J, Ramanathan RK, Rath L, Fu P, Chak A, Krishnamurthi S, Brell J, Ingalls S, Hoppel CL, Ivy P, Remick SC. Phase II and pharmacokinetic trial of rebeccamycin analog in advanced biliary cancers. Cancer Chemother Pharmacol. 2009 Dec;65(1):73-8. doi: 10.1007/s00280-009-1005-x. Epub 2009 Apr 28.</citation>
    <PMID>19399502</PMID>
  </results_reference>
  <results_reference>
    <citation>Dowlati A, Posey J, Ramanathan RK, et al.: Multicenter phase II and pharmacokinetic study of rebeccamycin analogue (RA) in advanced biliary cancers. [Abstract] Proceedings of the American Society of Clinical Oncology 22: A-1070, 2003.</citation>
  </results_reference>
  <verification_date>June 2010</verification_date>
  <study_first_submitted>July 5, 2000</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>June 9, 2010</last_update_submitted>
  <last_update_submitted_qc>June 9, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 11, 2010</last_update_posted>
  <responsible_party>
    <name_title>Afshin Dowlati MD</name_title>
    <organization>Ireland Cancer Center at University Hospitals Case Medical Center, Case Comprehensive Cancer Center</organization>
  </responsible_party>
  <keyword>localized unresectable adult primary liver cancer</keyword>
  <keyword>advanced adult primary liver cancer</keyword>
  <keyword>unresectable gallbladder cancer</keyword>
  <keyword>unresectable extrahepatic bile duct cancer</keyword>
  <keyword>adult primary hepatocellular carcinoma</keyword>
  <keyword>cholangiocarcinoma of the gallbladder</keyword>
  <keyword>cholangiocarcinoma of the extrahepatic bile duct</keyword>
  <keyword>adult primary cholangiocellular carcinoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Neoplasms</mesh_term>
    <mesh_term>Gallbladder Neoplasms</mesh_term>
    <mesh_term>Bile Duct Neoplasms</mesh_term>
    <mesh_term>Cholangiocarcinoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

